The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Https://www.chinadaily.com.cn/a/202306/19/WS64906f59a310bf8a75d6ab99.html
Https://www.thisismoney.co.uk/money/mortgageshome/article-12202409/House-prices-fell-just-82-June-despite-mortgage-chaos-says-Rightmove.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.12939511.1794328167.1687121752-44603416.1681110231&_gl=1*l6575d*_ga*NDQ2MDM0MTYuMTY4MTExMDIzMQ..*_ga_XE0XLFFF16*MTY4NzE5NDA5Ny4zOS4wLjE2ODcxOTQxMDEuMC4wLjA.
Thanks Gixer that makes the process a bit clearer, as it seems the animal testing is the last submission in the process to SAMR and the mouse trial has just been completed we might not be that far away (wishful thinking) Here’s hoping for a better week ,.
Gix good recap , I notice this paragraph from your finds,"..............................................”Notably, SAMR also created a five-year monitoring period of the new claim, during which the company obtaining the approval of the claim is obligated to collect a range of data, e.g., sales numbers, consumer feedback, etc., and submit annual reports to SAMR for review. During these five years, the new claim is proprietary to the company, and others may not use it. After the end of the monitoring period, if no issues are observed, SAMR will add the new claim to the approved list of claims for health foods. Through such listing, anyone can use the new claim on their health foods.[3]”. What do you or anyone,make of this ,, it seems to me that SAMR work with the company to obtain the new claim but there seems to be the need for 5 years collaboration to achieve this ,in whichever case we could be in the 5th year ! Could this be the cause of the long delay ?
If anyone can get this download it might have some useful info. https://www.tmogroup.asia/downloads/china-health-supplements-market-data-pack-april-2023-en-free/
An open offer at say .6p and 100m shares would solve the funding problem as far as I’m concerned , wouldn’t be too much dilution and give the company £600 k to take us forward , a bit simplistic but then I’m not running a small company with massive potential.
And it’s DSM who will have to deal with our renewed interest global player ( uni/CC) “ In June 2022 Provexis and DSM announced a new long-term partnership relating to the gut microbiome patent application which the Company filed in June 2022. New products arising from this collaboration are expected to be dealt with by DSM's Premix and Market-Ready Solutions businesses.“